Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with postmenopausal osteoporosis~Exclusion Criteria:~* Bilateral hip replacements~* Esophageal abnormalities~* Metabolic bone disease (example - Vitamin D deficiency)~* Medications that would affect the breakdown or build-up of bone turnover

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alendronate 70 mg (Type: EXPERIMENTAL): Alendronate sodium, 70 mg, orally once weekly for up to 24 months
- Risendronate 35 mg (Type: ACTIVE_COMPARATOR): Risendronate, 35 mg, orally once weekly for up to 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).